Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com Contacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
(Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
(Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished ... the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Medicine at the University of Arizona College of Medicine. He also serves as Medical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):